Peter Attia MD404 ‒ Mental health beyond neurotransmitters: hormones in psychiatry, psychedelic therapies, & more
Peter Attia MD
A career pivot into endocrinology 0:00
Lorenzo (referred to by the host as Lionus in the transcript, likely a transcription of "Lorenzo" or similar) explains that after roughly 30 years practicing psychiatry, he felt he had stopped learning as much as he wanted and made a deliberate pivot toward studying endocrinology alongside psychiatry. He describes himself as a humanistic, existentially oriented psychiatrist who uses psychopharmacology as his working tool, with particular expertise in bipolar spectrum disorders. Even in cases where medication produced dramatic symptom reduction, he noticed patients often still felt ambivalent about their treatment, which led him to conclude that psychiatry tends to aim at reducing symptoms rather than restoring the fuller human experience that makes life feel worthwhile.
Psychiatry without biomarkers 6:02
He points out something unusual about psychiatry compared to other medical fields: there are no measurable biomarkers, blood tests, or imaging findings that can confirm a diagnosis like depression or bipolar disorder. Diagnosis rests instead on the clinician's subjective interaction with the patient, though he notes that diagnosis and drug choice do not always move in lockstep. He trained at Harvard in a program that combined psychotherapy and psychopharmacology, which shaped his preference for treating the whole person rather than splitting therapy and medication into separate tracks.
SSRIs, SNRIs, and older drugs 10:32
He walks through the history of psychiatric drug classes, starting with older tricyclic antidepressants and MAO inhibitors, which carried serious risks including lethal overdose potential and, for MAOIs, dangerous reactions to foods containing tyramine, the so-called cheese reaction. SSRIs, beginning with fluoxetine (Prozac), marked a shift toward safer, more targeted drugs that block the reuptake of serotonin. He notes that raising serotonin can paradoxically lower dopamine and norepinephrine, which can leave patients symptom-free but emotionally blunted or not fully vital. SNRIs, such as venlafaxine and desvenlafaxine, balance serotonin and norepinephrine and can reduce that blunting or cognitive dulling, though pure serotonin amplification is still preferred for conditions like OCD and PTSD, while SSRIs are, somewhat surprisingly, often more effective for anxiety than for depression itself.
Diagnosing bipolar depression 24:31
Discussing bipolar disorder, he explains that most patients arrive without knowing they have it, and he is often the one to first raise the hypothesis. Many present primarily with depression rather than mania, especially in bipolar II, where the elevated state is hypomania rather than full mania, and can actually be adaptive; he estimates roughly a third of his patients have used hypomanic drive to achieve notable success. The critical clinical distinction is that bipolar depression responds differently to antidepressants than unipolar depression does, sometimes triggering mood cycling, agitated hypomania, or mixed states. The correct approach is to stabilize with a mood stabilizer like lamotrigine or lithium first, both of which can treat depression directly, before cautiously considering an antidepressant.
Depression through an evolutionary lens 32:00
The conversation turns to whether depression, dysthymia, and anhedonia might have had evolutionary value, comparing them to anxiety and hypomania, which seem more obviously protective. He suggests diurnal mood variation and hypersomnia might once have kept people sheltered during hours with less opportunity for mating or resource gathering, protecting survival. The host questions whether some conditions, like atherosclerosis, are simply modern "luxury problems" with no evolutionary logic, then offers his own example: the same apolipoprotein biology that causes atherosclerosis also once allowed humans to carry enough cholesterol to fuel large brains during nutrient scarcity, a trait that only becomes harmful now that food is abundant.
Is depression ever adaptive 36:30
The conversation opens with a question about whether depression might serve some purpose, letting people appreciate the absence of low mood. The guest separates clinical depression from everyday sadness, saying clinical depression is genuinely bad, takes a huge toll, raises medical risk, and can be lethal. He allows that it can force a radical reappraisal of one's priorities and shake up an old model of the world, but insists there are better paths to that insight than suffering through depression.
Is depression more common now 39:30
Peter asks whether clinical depression is truly more prevalent today than thousands of years ago, or even a decade ago. The guest points to compounding modern pressures, environmental anxiety, wildfires, and existential questions raised by artificial intelligence outpacing human intellectual function. Peter pushes back by noting that material life today is vastly better than a thousand years ago, prompting a discussion about whether the comparison should be economic or relational.
Isolation, comparison, and modern triggers 41:03
The guest lists social media, digital isolation, algorithm-driven distorted worldviews, declining rates of sex and romantic relationships, rising use of online pornography, falling fertility, and widening socioeconomic divides as drivers of mental strain. He contrasts this with a story Peter shares about a physician working with a population in Sudan's Nuba Mountains who reports almost no depression despite war and hardship, attributing it to tight-knit families and shared purpose. Both agree the price of modernity may be that comforts and technologies remove the natural constraints that once kept people outdoors, socially connected, and physically active, meaning people now must deliberately choose behaviors, like disconnecting from phones or going outside, that used to happen automatically.
Sleep, biology, and distress tolerance 49:02
Peter describes research suggesting hunter-gatherers did not suffer insomnia because circadian rhythm, adenosine, and cortisol naturally stayed in sync, while modern life works against all three. He introduces his own mental model of a distress tolerance window, the capacity to absorb stress before becoming irritable, and notes that exercise, sleep quality, and even untreated pain dramatically widen or narrow that window. The guest agrees these foundational biological factors, including endocrinology, inflammation, metabolism, and stress circuitry, are all challenged by modern life and are part of what psychiatry must account for, even though psychiatrists vary in how much they address nutrition, exercise, and sleep directly.
Why endocrinology drew him in 54:02
The guest explains that his interest in endocrinology began around five years earlier, sparked by watching how reinterpretation of the Women's Health Initiative reshaped hormone prescribing in general medicine and made him suspect psychiatry had similarly underappreciated hormones. He pursued formal training, including certification in bioidentical hormone replacement therapy, and came to see neural circuits and the endocrine system as inseparable. Looking back at the two decades following the WHI, he recalls a sense that women losing estradiol and men denied testosterone both experienced an erosion of adaptive capacity and function across multiple areas of life.
Estradiol as a brain regulator 1:02:30
The guest describes estradiol as a constitutive, pleiotropic, multi-system regulator of neurotransmitters, meaning it is built into brain architecture and acts on many systems at once, including serotonin, dopamine, GABA, acetylcholine, and glutamate pathways. Unlike psychiatric drugs that amplify specific signals, estradiol modulates the conditions under which neurotransmission happens, working through membrane estrogen receptors and estrogen response elements deep within gene transcription, for example boosting serotonin synthesis via tryptophan hydroxylase and dopamine via tyrosine hydroxylase. He explains that estradiol evolved this broad role because successful reproduction requires more than conception, it requires nurturing, social bonding, and resource gathering, which is why low estrogen can affect cognition, mood, and anxiety simultaneously.
Why hormone loss affects people differently 1:04:01
Asked why some women barely notice estrogen withdrawal while others find it incompatible with normal life, the guest points to genetic differences in receptor structure and function rather than absolute hormone levels, plus the role of actual fluctuations and oscillations in hormone levels, which explains conditions like PMDD tied to dropping allopregnanolone. He adds that a woman's overall adaptive capacity, shaped by sleep quality, social support, caregiving burdens, work stress, and metabolic health, strongly influences how well she withstands menopausal change, and that hormone loss itself can worsen metabolic health and motivation in a vicious cycle.
Testosterone in men and women 1:07:00
The guest explains that men convert testosterone into estradiol through aromatization, so testosterone acts as a precursor as well as a primary hormone in its own right, especially for dopamine-linked reward and executive function pathways. Declining testosterone in men, called andropause, tends to be gradual and can produce a dulling of motivation, reward-seeking, and cognitive function resembling subclinical ADHD, alongside reduced vitality and libido. Women depend on testosterone heavily for libido but are less reliant on it for mood or sleep, and despite testosterone numbers looking tiny on lab reports, once units are normalized a woman's testosterone level is actually about ten times higher than her estradiol level, though still roughly a tenth of a man's testosterone level.
Restoring Testosterone Without Direct Replacement 1:11:31
The conversation covers ways to raise a man's own testosterone rather than giving it directly, mainly through hCG, which mimics luteinizing hormone and signals the testes to produce more testosterone, or through Clomid and enclomiphene, which block estradiol and testosterone receptors at the hypothalamus so the pituitary ramps up LH and FSH. Despite normal or high lab numbers on these drugs, men often report feeling dissatisfied, a mismatch between blood levels and how they actually feel, something the guest calls unexplained but consistently observed in practice. Clomiphene's main real-world draw is that it preserves fertility and endogenous hormone production, is cheap, oral, and unregulated, unlike testosterone and hCG which are controlled substances. hCG works peripherally without the central receptor block and fixes lab numbers reliably, but it's expensive, injectable, and inconvenient, and like Clomid, it tends to normalize numbers without fully resolving symptoms compared to direct testosterone cypionate injections.
How Progesterone Rises and Falls 1:14:31
Progesterone stays flat for the first fourteen days of a woman's cycle, then rises after ovulation as the corpus luteum prepares the uterine lining for implantation. If implantation doesn't occur, that lining sheds as the period, and progesterone crashes. The key point is that women don't feel bad when progesterone is simply low during the flat follicular phase; the mood symptoms come specifically from the fall from high back to low. This same pattern shows up dramatically after childbirth, when estradiol drops from roughly 30,000 to 30 and progesterone drops from several hundred to less than one within 24 to 48 hours, a collapse the guest describes as astonishing given how well most women cope with it.
Severe Postpartum Depression and Psychosis 1:18:04
The most extreme form of postpartum depression appears within about a week of childbirth, usually still in the hospital, and affects fewer than one percent of women. It can involve sudden suspicion of hospital staff, hypervigilance about the baby's location, intense separation anxiety, and OCD-like intrusive fears of harming the child without any real intent to do so. This severe form is treated with a fast-acting synthetic version of allopregnanolone, a natural breakdown product of progesterone, first available as an IV infusion called brexanolone and now as an oral drug called zuranolone, typically given alone rather than alongside a new SSRI, though existing antidepressants aren't stopped.
The More Common, Delayed Postpartum Presentation 1:20:01
Most postpartum depression looks different: women seem fine at first, then over weeks or months fail to return to themselves, sometimes with no obvious identity shift or loss of support to point to. Evaluation follows the same approach as any depression assessment, weighing prior history, bipolar risk, and life circumstances. Treatment length is framed around the patient's baseline: someone well for decades before one episode might expect 8 to 12 months of medication before a slow taper, while someone with pre-existing low-grade dysthymic tendencies may find their new baseline on medication is actually better than their old one, meaning the pregnancy exacerbated something already there.
Thyroid Hormone and Mood 1:27:02
TSH reflects what the pituitary thinks the thyroid is doing, but it's only a signal, not the hormone itself, so a "normal" TSH in the upper half of the reference range can mask real thyroid hormone deficiency. Free T4 is the value to watch, since T4 is a prodrug converted centrally in the brain and peripherally in the body into active T3. Low thyroid function tends to show up as depression, while hyperthyroidism shows up as physical anxiety, racing heart, sweating, restlessness, and insomnia, illustrated by one case of a thyroid nodule causing a TSH of zero and a near thyroid-storm presentation requiring endocrinology referral.
T3 for Treatment-Resistant Depression 1:32:31
For hard-to-treat depression, the guest sometimes prescribes immediate-release T3 (cytomel) alone, dosed twice daily starting as low as 2.5 micrograms and occasionally rising to 25 micrograms twice a day, even when thyroid labs look unremarkable. This is used after failed trials of SSRIs, SNRIs, bupropion, lithium augmentation, and atypical antipsychotics like Abilify, Rexulti, or Vraylar, which carry their own risks such as irreversible tardive dyskinesia. Drugs are removed in order of efficacy through shared decision-making with the patient, not simply by side-effect profile.
Cortisol as the Hardest Axis 1:40:32
Among four hormonal axes the guest thinks about, thyroid, androgen, adrenal cortical, and fuel partitioning, cortisol is the hardest because most people suffer from too much of it and there is no direct pill to fix that, unlike deficiencies elsewhere. Chronic cortisol elevation reflects an ancient survival system for threat detection and hypervigilance turned maladaptive when it runs constantly instead of acutely. Rather than treating cortisol as the primary problem, the guest treats it as a signal pointing to an underlying stressor, caregiving burden, overwork, or unmanaged illness, and works with the patient to address that root cause directly, deliberately avoiding clinical jargon and instead talking in plain, everyday terms about what's driving it.
A Menopause Clue to Bipolar Disorder 1:45:30
A perimenopausal woman came to the guest asking for hormones, describing herself as having always been the strongest, most high-energy person she knew. When he asked about her twenties and thirties, she described starting several companies, spending heavily, traveling constantly, and having thoughts race faster than she could write them down. Investigating her hormones alongside this history revealed that menopause was actually the trigger uncovering a long-neglected bipolar disorder. He started her on lamotrigine, which became, in his words, a road to restitution of her life's narrative, finally giving her an explanation for difficulties she had carried her whole adult life.
When an Antidepressant Backfires 1:50:00
The same woman had once seen a psychiatrist for what looked like a depressive crash after an extended hypomanic period of intense productivity. An antidepressant seemed miraculous at first, but within weeks her racing thoughts returned worse than ever and she couldn't sleep, so she stopped the medication and never returned to that doctor. Once off it, she went back to her baseline hypomanic roller coaster. The guest notes that no one actually knows, on a receptor or biological level, what is happening in her brain to cause the hypomania, which he finds remarkable given how confidently she can be treated despite that gap in understanding.
How Ketamine Works for Depression 1:51:00
Ketamine, unrelated to MDMA despite the similar-sounding name, is an NMDA receptor antagonist that blocks receptors normally inhibiting GABA interneurons connected to glutamate. The result is a sudden, massive release of glutamate, triggering the mTOR pathway, protein synthesis, and rapid synaptic remodeling, producing fast-onset and fast-fading neuroplasticity. Clinically this means a patient on the edge of hospitalization for suicidal risk can receive a ketamine infusion and see that risk dissipate dramatically, even though the underlying depression often doesn't resolve. The guest generally uses it as a bridge to find a longer-term solution rather than the solution itself, and notes it is time-consuming, expensive, given intravenously under monitoring, and produces a dissociative effect whose relief can last anywhere from days to longer, for reasons that remain poorly understood. He also voices concern about unsupervised recreational use, calling it Russian roulette without proper control.
A Puzzling Psilocybin and Alzheimer's Case 1:57:00
The hosts discuss a widely circulated case report of a Japanese woman with a decade-long diagnosis of severe Alzheimer's, including incontinence and near-total loss of speech, who reportedly showed dramatic improvement after receiving five grams of psilocybin. Both hosts are skeptical, noting the report lacks neuroimaging or real metrics, and that surviving ten years with genuinely severe Alzheimer's is itself unusual. One alternative explanation raised is that PTSD, rather than Alzheimer's, may have caused a regression that the psilocybin reversed. They connect this to Robin Carhart-Harris's relaxed beliefs under psychedelics model, where psychedelics open a window of heightened neuroplasticity that can help adjust maladaptive beliefs underlying depression and anxiety, a mechanism the guest compares to how estradiol also drives plasticity through BDNF and NMDA-glutamate pathways.
Personal Experiences with Ketamine and Psilocybin 2:02:31
One host describes a therapeutic ketamine session as devastating, comparing it to Guantanamo Bay for his soul, with no positive outcome, leaving him firmly resistant to repeating it and cautious with patients curious about these agents. He contrasts this with a profoundly positive psilocybin experience roughly a decade earlier, an out-of-body journey in which he relived a vivid childhood memory from his parent's perspective rather than his own, producing lasting gratitude and empathy that he says has stayed with him ever since. Later attempts to recreate that experience, even with extensive preparation and therapist support, failed and at times caused real harm, leading him to decide roughly two years ago to stop. He also notes his own unusual drug sensitivity, needing two to three times the typical dose of caffeine, alcohol, or psilocybin to feel any effect at all, which may explain why his experiences diverge so sharply from the norm.
Where Psychedelic Therapy Might Go Next 2:13:30
Looking ahead, the guest is hopeful researchers will find ways to shift the risk-benefit balance of psychedelics, whether through new molecules, refined set-and-setting strategies, or combination pharmacotherapy that avoids blocking the serotonin 2A receptor these drugs depend on. The two indications both hosts find most promising are MDMA for PTSD and psilocybin for end-of-life depression and related distress, where the guest argues the risk-reward calculation shifts given how severe the baseline suffering already is. He suggests MDMA's empathy-boosting, or entactogenic, effects may suit PTSD cases centered on reconciliation, while acknowledging PTSD is a highly varied condition. Both hosts agree the field's benefits and dangers are equally real, and that patients need honest caution rather than only hearing the encouraging stories.
AI-generated summary. It can be wrong or incomplete - check anything that matters against the original.
